retatrutide news recency 3 🚨Breaking: Retatrutide's first Phase T2D data just dropped. ▸ A1C: −2.0% at 40 weeks ▸ Weight: −36.6 lbs (−16.8%) at 12 mg ▸ No weight loss plateau — curve still descending New Retatrutide Phase 3 Trial

It activates two receptors simultaneously: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide)

The hormone signals your pancreas to produce insulin, tells your brain that you're getting full and slows down how quickly food leaves your stomachkeeping you satisfied longer after meals

That proactive mindset, planning ahead rather than reacting after the fact, is the single most useful shift I can encourage in anyone navigating significant weight change through this medication class, regardless of where they are in that journey today

FAQ: Retatrutide + MOTS-c Can MOTS-c preserve muscle during Retatrutide therapy

See below to learn what you can do to manage those issues

And here, the differences between dual and triple agonism create meaningfully different benefit profiles